-
After the Spring Festival, the Central Commission for Discipline Inspection issued a document naming medical and pharmaceutical corruption for the first time
Time of Update: 2021-03-25
Entering February , many key few were investigated According to Cyberlan’s observations, the National Supervision Commission of the Central Commission for Discipline Inspection previously published an article on the official website of “Anti-corruption in the Medical Field: Someone Asks the Pulse with One Hand, and Swallows Gold in His Sleeve”, pointing out that hospital leaders such as the hospital director, as a key minority, are involved in many cases The problem.
-
Pharmaceutical giants are competing: from AI to quantum computing, the fast track of drug research and development is ready to go
Time of Update: 2021-03-25
Representative company: BenevolentAI, StandigmPhase 2: After discovering the drug candidate and determining the target, the drug developer needs to screen out a compound that can interact with it in a desired way from thousands or even millions of potential compounds, and also need to avoid this compound pair Non-target sites produce side effects.
-
A pharmaceutical company fined 50,000 yuan for its unqualified properties of Drynaria fortunei
Time of Update: 2021-03-25
The parties involved in the production and sale of the inferior medicine Rhizoma Drynariae (Bone Rhizoma Drynariae) violated the provisions of Article 49, Paragraph 1 of the "Drug Administration Law" (amended in 2015).
22 yuan from the sale of inferior medicine Rhizoma Drynariae (Bone Rhizoma Drynariae);4.
-
A pharmaceutical company has been warned of 5 defects
Time of Update: 2021-03-25
, Ltd. Inspection time: 2021-01-12Inspection basisThe "Drug Administration Law of the People's Republic of China", "Drug Production Supervision and Administration Measures", "Drug Production Quality Management Regulations (Revised in 2010)" and its appendices and other relevant laws and regulations, and six inspections of drug production links in 2021.
-
New Understanding of the Mechanism of Antidepressants
Time of Update: 2021-03-25
The author of this article believes that the poor binding of these drugs to the true target TRKA is the reason .
In fact, it is not easy to say how these antidepressant drugs are on average according to modern clinical trial standards.
-
Junshi Bio-PD-1 second-line treatment of nasopharyngeal carcinoma approved in China
Time of Update: 2021-03-25
The acceptance number associated with the drug approval document obtained this time is the same as the acceptance number of last year's listing application included in the priority review, which means that teriprizumab is officially approved in China for the second-line treatment of recurrent/metastatic nasopharyngeal carcinoma!The indication application is based on a multi-center, open-label, phase 2 key registration clinical study (POLARIS-02).
-
National Medical Insurance Bureau: The medical insurance fund is no problem with the burden of the new crown vaccine
Time of Update: 2021-03-25
The medical insurance fund is mainly borne by using the balance of the past years, and does not affect the income and expenditure of the fund in the current period, that is to say, it will not affect the people's medical treatment in the current period.
-
Summary | Recent changes in senior personnel in the pharmaceutical industry
Time of Update: 2021-03-25
4. jCyteJCyte appointed Samir Mody as chief commercial officer, and Friedrich Asmus as senior vice president of clinical development and medical affairs.
Asmus previously served as Vice President of Clinical Development at ProQR Therapeutics in ophthalmic biotechnology, while Centeno has held positions at Boston Scientific, Hologic and AltheaDx. 5.
-
Amgen KRAS inhibitor receives FDA priority review for the treatment of non-small cell lung cancer
Time of Update: 2021-03-25
On February 17, Amgen announced that the US FDA has granted the company's KRAS G12C inhibitor sotorasib priority review for the treatment of locally advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutations.
Retrieved February 16, 2021, from https:// /fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer-301229256 .
-
Heavy policy introduced 20 billion Chinese medicine formula granules market is changing
Time of Update: 2021-03-25
Medical News February 22 The introduction of the heavy policy, the 20 billion market is facing the changing situation On February 18, the website of the State Food and Drug Administration published a number of articles on the development of TCM formula granules to further interpret the importance of the formulation of national standards for TCM formula granules.
-
A large number of medicines can be reimbursed from next month
Time of Update: 2021-03-25
Beijing: Improve the policy of special diseases in outpatient clinics, currently there are 17 kinds of diseasesIt is reported that Beijing has included all the 119 drugs added by the state into the city's medical insurance drug list.
-
See the micro-knowledge-the past of adalimumab and the future of biosimilar drugs
Time of Update: 2021-03-24
In terms of the market performance of adalimumab, according to the statistics of the PDB drug comprehensive database, after the entry of adalimumab into my country’s medical insurance at the end of 2019, despite the impact of the epidemic, the sales volume still increased greatly, and the total sales amount reached 59 million yuan.
-
The first domestic Junshi PD-1/TGFβ double antibody clinical application was accepted
Time of Update: 2021-03-24
On February 24, the official website of CDE showed that the clinical application for Junshi Bio-JS201 injection was accepted. JS201 is a PD-1/TGFβ bispecific antibody. At present, no other company i
-
CDE publishes these 30 varieties of pharmacy research or more stringent!
Time of Update: 2021-03-24
"Because the clinical value of these varieties is clear, and reference preparations cannot be recommended, the consistency evaluation work can be further simplified and pharmaceutical research can be carried out.
-
The National Health Insurance Administration announced that the first issue of 2021 exposed a typical case of a total of nine cases
Time of Update: 2021-03-24
The judgment by the local court is as follows: The defendant, Yang Moumou, a legal person from Heshuo Silk Road Yikang Traditional Chinese Medicine Hospital, committed fraud and was sentenced to three years in prison, suspended for five years, and fined RMB 100,000.
-
Pfizer's "Vupanorsen Injection" was first approved for clinical use in China
Time of Update: 2021-03-24
It is an RNAi drug targeting liver angiogenin-like protein 3 (ANGPTL3) developed based on Ionis’ ligand-conjugated antisense (LICA) technology platform to reduce the risk and severity of cardiovascular diseases Hypertriglyceridemia.
-
Guidelines for direct settlement of general outpatient expenses across provinces are here
Time of Update: 2021-03-24
Regarding the specific operation of inquiring whether filing is required, you can follow the official account of the National Medical Insurance Administration, click on "My Medical Insurance"-"Public Inquiry"-"Opening a Coordination Area for Direct Settlement of General Outpatient Expenses across Provinces" in the navigation bar below, and select the desired query Click the query button after the provinces to search.
-
Junshi Biotech and AstraZeneca Pharmaceuticals signed an exclusive promotion agreement for Tuoyi
Time of Update: 2021-03-24
On February 28th, Junshi Biopharmaceuticals announced that it had signed an "Exclusive Promotion Agreement" with AstraZeneca Pharmaceuticals Co.
In addition, as consideration for the promotion rights granted by Junshi Biotechnology to AstraZeneca, AstraZeneca agreed to pay a down payment to the company after the urothelial cancer indication was approved.
-
The third batch of medical insurance products has been 3/4 times, 9 times, 10 times, and the highest is 24 times. Come and see if there is your home?
Time of Update: 2021-03-24
This article attempts to answer three questions:What changes will happen to the innovative drug market?Is it necessary for innovative drugs to enter medical insurance through the National Talks?How to solve the last mile of medical insurance?01 What changes will happen to the innovative drug market?01 What changes will happen to the innovative drug market?Innovation is leading changes in the competitive landscape of the pharmaceutical industry.
-
Deqi Pharmaceutical's Selinexor New Drug Listing Application Receives Priority Review by NMPA
Time of Update: 2021-03-24
On February 24, Deqi Pharmaceuticals announced that the National Medical Products Administration (NMPA) has awarded the world’s first Selective Inhibitor of Nuclear Export ("SINE") ATG-010 (selinexor, XPOVIO®) New drug application (NDA) priority review qualification for the treatment of patients with refractory and relapsed multiple myeloma (rrMM).
